ArticleClinical medicine (London, England)2023
Crohn's disease: an update.
Article in Clinical medicine (London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 4 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- Specific alterations in the gut microbiome and metabolome across disease locations of Crohn's disease: a systematic review.BMC gastroenterology · 2026Pooled it
- Pooled it
- Evaluating Quality of Life in Surgically Treated IBD Patients: A Systematic Review of Physical, Emotional and Social Impacts.Medicina (Kaunas, Lithuania) · 2025Pooled it
- Quantitative Alterations in Short-Chain Fatty Acids in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.Biomolecules · 2025Pooled it
- Mesenchymal Stem Cells Alleviate Crohn's Disease by Regulating CBS-Mediated Ferroptosis.Immunity, inflammation and disease · 2026Article
- Development of a Claims-Based Algorithm and Validation Through Medical Chart Review to Identify Patients with Crohn's Disease-Related Fibrostenosis: A Retrospective Observational Study in the United States.Advances in therapy · 2026Article
- Translational Animal Models in Colitis: From Rodents to Pig and Minipig Platforms.International journal of molecular sciences · 2026Review
- Assessing the Impact of Crohn's Disease on Foot Health-Related Quality of Life: A Case-Control Study.International wound journal · 2026Observational
- Magnetic Resonance Enterography Predicts Long-Term Outcomes in Crohn's Disease: A Systematic Review and Meta-Analysis.JGH open : an open access journal of gastroenterology and hepatology · 2026Review
- Age-Related Microbiota Signatures in Inflammatory Diseases: Comparative Insights into Paediatric and Adult Crohn's Disease, Ulcerative Colitis, and Spondyloarthritis.Mediterranean journal of rheumatology · 2026Review
- Liver X receptor: A potential target for inflammatory bowel disease and colorectal cancer (Review).Molecular medicine reports · 2026Review
- Crohn's Disease in Malaysia: Could Application of the Precautionary Principle Reduce Future Incidence?Microorganisms · 2026Review
- Article
- Unveiling Genital Crohn's Disease: Clinical Complications, Diagnosis, and Treatment, a Comprehensive Review of Case Reports.Gastro hep advances · 2026Review
- Shared inflammatory architecture and therapeutic tensions between psoriasis and Crohn's disease.Frontiers in immunology · 2026Review
- Immunomodulators and advanced therapies for maintenance of remission in Crohn's disease: systematic review and network meta-analysis.Therapeutic advances in gastroenterology · 2026Article
- Artificial intelligence in optimizing antimicrobial therapy for gastro-renal disorders.Frontiers in cellular and infection microbiology · 2026Review
- Current status of 5-aminosalicylic acid in Crohn's disease treatment: a nationwide survey and analysis of perspectives and practice patterns among inflammatory bowel disease physicians.Frontiers in gastroenterology (Lausanne, Switzerland) · 2026Article
- Orbital myositis last year and now Crohn's disease: A case report of a rare association.SAGE open medical case reports · 2026Article
- Efficacy and tolerability of janus kinase inhibition strategies for moderate-to-severe Crohn's disease: A systematic review and bayesian network meta-analysis.Therapeutic advances in gastroenterology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Crohn's disease (CD) is a chronic, relapsing and remitting inflammatory bowel disease (IBD) that is increasing in incidence and prevalence globally. Management aims to achieve endoscopic healing, symptom resolution and improvement in quality of life. Therapeutic approaches in CD vary depending on disease phenotype. Thiopurines are important in steroid-sparing maintenance therapy, while anti-tumour necrosis factor agents play a fundamental role, especially in fistulising CD. Suboptimal response to these medications may require escalation to other immunosuppressive and biologic therapies, and surgical intervention is still required in a proportion of patients. Tailoring treatment to target specific patient phenotypes, disease severity and patient wishes is becoming more feasible with the growing array of therapeutic options in CD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.